London, December 19, 2023
Userlane and Generis are forming a strategic partnership to accelerate user adoption of the CARA platform in regulated industries.
Generis is a UK-headquartered developer of data, content, and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis’ flagship CARA life sciences platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, regulatory, R&D, and safety to clinical, quality GxP, CMC, pharmacovigilance, medical information, and medical affairs applications.
The CARA platform helps organizations streamline complex regulated business processes, data, and content on a single platform. It facilitates the instant creation, localization, and reuse of information, accelerating work and ensuring accuracy across organizational processes.
Userlane’s platform offers tailored process guides, on-demand support, and efficient onboarding and training processes when working with the CARA platform. It also allows enterprise customers to track and analyze software adoption within their organizations.
This partnership lets companies use the best of both technologies. Integrating Userlane into the CARA platform brings significant benefits, including:
- Quicker deployment and training on the CARA platform
- Increased user satisfaction
- Improved customer communication
- Greater adoption of new features and updates on the CARA platform
“This partnership addresses a crucial challenge many companies face: user adoption. Despite the widespread push toward technology adoption in regulated industries, adoption rates have varied. The integration with Userlane supports a smooth transition from complex systems to the comprehensive and feature-rich CARA Platform.”
James Kelleher, CEO, Generis
Learn more about the Userlane partner program.
